Meeting Report
Neratinib for Extended Anti-HER2 Therapy in Early Breast Cancer
Presented by G. Thomas Budd,(1) MD, and Wendy H. Vogel,(2) MSN, FNP, AOCNP®
1)Taussig Cancer Center at Cleveland Clinic, Cleveland, Ohio; 2)Wellmont Cancer Institute, Kingsport, Tennessee
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2018;9(3):298–302 |
https://doi.org/10.6004/jadpro.2018.9.3.5 |
© 2018 Harborside™
ABSTRACT
Neratinib following the completion of trastuzumab has been shown to reduce the risk of disease recurrence for patients with HER2-positive early breast cancer in whom extended adjuvant therapy seems advisable. In clinical trials, the most common side effect of neratinib and other anti-HER2 therapies was diarrhea. Presenters at JADPRO Live clarified the findings of trials studying the benefit of differing prophylactic regimens with loperamide, budesonide, and colestipol.
For access to the full length article, please
sign in.
